Evidence map›Paper›PMID 40748523›Full record

ReviewCurrent oncology reports2025

Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive Chemotherapy.

Alex Bataller, Nicholas J Short, Naval Daver, Musa Yilmaz, Hagop Kantarjian, Farhad Ravandi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alex BatallerDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Unit 428. 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Nicholas J ShortDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Unit 428. 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Naval DaverDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Unit 428. 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Musa YilmazDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Unit 428. 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Hagop KantarjianDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Unit 428. 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Farhad RavandiDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Unit 428. 1400 Holcombe Blvd, Houston, TX, 77030, USA. fravandi@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewYounger patients with acute myeloblastic leukemia with FLT3 mutations (FLT3-mutated AML) benefit from the addition of FLT3 inhibitors to intensive chemotherapy. However, patients who are not eligible for intensive chemotherapy have poor outcomes with standard low-intensity treatments. In this review we assess the current state of treatment strategies for patients with FLT3-mutated AML who are not candidates for intensive chemotherapy. RECENT

findingsThe addition of FLT3 inhibitors to standard low-intensity AML treatments (doublet) has increased response rates, although in a randomized clinical trial this did not improve survival. The addition of venetoclax to these regimens (triplet) shows promising activity (overall response rate of approximately 90%). However, myelotoxicity is common, and dose adjustments are usually necessary. Combinations of low-intensity treatments with venetoclax and potent FLT3 inhibitors are feasible and have shown encouraging outcomes. Dose adjustments are essential to reduce treatment-related myelosuppression.

Indexed as

Antineoplastic Combined Chemotherapy Protocolsfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteProtein Kinase InhibitorsBridged Bicyclo Compounds, HeterocyclicHumansMutationSulfonamidesBridged Bicyclo Compounds, HeterocyclicFLT3 protein, humanfms-Like Tyrosine Kinase 3Protein Kinase InhibitorsSulfonamidesvenetoclaxAcute myeloid leukemiaAMLFLT3Low-intensity treatmentVenetoclax

Identifiers

PMID40748523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.